About
Radioligand therapy
Areas of Focus
Categories
RadiopharmaceuticalsNorway
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
83
By Phase
PHASE1: 1EARLY_PHASE1: 1
By Status
NOT_YET_RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
Today
Hover over trial bars to see details
Recent Trials
NCT07214961Lead Sponsor
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
PHASE1Not yet recruiting
80 participants
Started: Sep 30, 2025 · Completed: Sep 30, 2033
NCT05725070Lead Sponsor
Phase 0/1 Study of 212Pb-NG001 in mCRPC
EARLY_PHASE1Completed
3 participants
Started: Mar 6, 2023 · Completed: Jul 6, 2023
Locations (1)
Headquarters
Oslo, Norway
Map
Loading map...